Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Other Non-Current Assets for 16 consecutive years, with $5.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Assets fell 71.57% to $5.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $5.6 million, a 71.57% decrease, with the full-year FY2024 number at $5.7 million, down 1.21% from a year prior.
  • Other Non-Current Assets was $5.6 million for Q2 2025 at Anika Therapeutics, down from $5.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $23.7 million in Q3 2021 to a low of $5.6 million in Q2 2025.
  • A 5-year average of $16.6 million and a median of $18.7 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: soared 78.97% in 2021, then plummeted 71.57% in 2025.
  • Anika Therapeutics' Other Non-Current Assets stood at $20.3 million in 2021, then dropped by 15.11% to $17.2 million in 2022, then plummeted by 66.75% to $5.7 million in 2023, then decreased by 1.21% to $5.7 million in 2024, then decreased by 1.87% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Other Non-Current Assets are $5.6 million (Q2 2025), $5.7 million (Q4 2024), and $11.3 million (Q3 2024).